This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Gutmann, D. H. Search for Related Content PubMed PubMed Citation Articles by Gutmann, D. H. Social Bookmarking                         What's this?

Using Neurofibromatosis-1 to Better Understand and Treat Pediatric Low-Grade Glioma

Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, gutmannd{at}wustl.edu

Relatively little is known about the seminal genetic events that trigger the development of low-grade gliomas in children. Genetically engineered mouse models of the neurofibromatosis-1—inherited tumor predisposition syndrome have identified key intracellular growth control pathways, defined the contribution of the tumor microenvironment to glioma growth, and helped researchers understand the genetic basis for glioma susceptibility. In addition, genetically engineered mouse low-grade glioma models have recently been used in preclinical therapeutic studies to evaluate the efficacy of particular biologically based therapies and to define outcome measures.

Key Words: Neurofibromin • astrocytoma • tumor microenvironment • preclinical therapeutics • brain tumor • genetically engineered mice

References

• CBTRUS 2005-2006 Primary Brain Tumors in the United States Statistical Report 1998-2002 Years Data Collected. Central Brain Tumor Registry of the United States. Available at: http://www.cbtrus.org. Accessed November 30, 2007.
• Louis DN, Ohgaki H, Wiester OD, et al, eds. WHO Classification of Tumours of the Central Nervous System. Vol 1. 4th ed. Geneva: WHO Press; 2007:312.
• Benesch M., Lackner H., Sovinz P., et al. Late sequela after treatment of childhood low-grade gliomas: a retrospective analysis of 69 long-term survivors treated between 1983 and 2003. J Neurooncol. 2006;78:199-205.[CrossRef][Medline] [Order article via Infotrieve]
• Mulhern RK, Palmer SL Neurocognitive late effects in pediatric cancer. Curr Probl Cancer. 2003;27:177-197.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Friedman JM, Gutmann DH, MacCollin M., et al. Neurofibromatosis: Phenotype, Natural History, and Pathogenesis. Baltimore, MD: Johns Hopkins Press; 1999.
• Listernick R., Charrow J., Greenwald M., et al. Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study. J Pediatr. 1994;125:63-66.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Guillamo JS, Creange A., Kalifa C., et al. Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): a retrospective study of 104 patients. Brain. 2003;126:152-160.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Gutmann DH, Donahoe J., Brown T., et al. Loss of neurofibromatosis 1 (NF1) gene expression in NF1-associated pilocytic astrocytomas. Neuropathol Appl Neurobiol. 2000;26:361-367.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Rodriguez FJ, Perry A., Gutmann DH, et al. Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients. J Neuropathol Exp Neurol. 2008;67:240-249.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Schmandt SM, Packer RJ, Vezina LG, et al. Spontaneous regression of low-grade astrocytomas in childhood. Pediatr Neurosurg. 2000;32:132-136.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Wimmer K., Eckart M., Meyer-Puttlitz B., et al. Mutational and expression analysis of the NF1 gene argues against a role as tumor suppressor in sporadic pilocytic astrocytomas. J Neuropathol Exp Neurol. 2002;61:896-902.[Web of Science][Medline] [Order article via Infotrieve]
• Kluwe L., Hagel C., Tatagiba M., et al. Loss of NF1 alleles distinguish sporadic from NF1-associated pilocytic astrocytomas. J Neuropathol Exp Neurol. 2001;60:917-920.[Web of Science][Medline] [Order article via Infotrieve]
• Bollag G., Clapp DW, Shih S., et al. Loss of NF1 results in activation of the RAS signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet. 1996;12:144-148.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Guha A., Lau N., Huvar I., et al. RAS-GTP levels are elevated in human NF1 peripheral nerve tumors. Oncogene. 1996;12:507-513.[Web of Science][Medline] [Order article via Infotrieve]
• Basu TN, Gutmann DH, Fletcher JA, et al. Aberrant regulation of RAS proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature. 1992;356:713-715.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Sharma MK, Zehnbauer BA, Watson MA, et al. RAS pathway activation and an oncogenic RAS mutation in sporadic pilocytic astrocytoma. Neurology. 2005;65:1335-1336.[Free Full Text]
• Janzarik WG, Kratz CP, Loges NT, et al. Further evidence for a somatic KRAS mutation in a pilocytic astrocytoma. Neuropediatrics. 2007;38:61-63.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Viskochil D., Buchberg AM, Xu G., et al. Deletions and a trans-location interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell. 1990;62:187-192.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Wallace MR, Marchuk DA, Andersen LB, et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science. 1990;249:181-186.[Abstract/Free Full Text]
• Xu GF, O'Connell P., Viskochil D., etal. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell. 1990;62:599-608.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Bollag G., McCormick F. GTPase activating proteins. Semin Cancer Biol. 1992;3:199-208.[Medline] [Order article via Infotrieve]
• Sebti SM, Hamilton AD Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues. Expert Opin Investig Drugs. 2000;9:2767-2782.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Karp JE, Lancet JE Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies. Cancer Invest. 2007;25:484-494.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Widemann BC, Salzer WL, Arceci RJ, et al. Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J Clin Oncol. 2006;24:507-516.[Abstract/Free Full Text]
• Mahgoub N., Taylor BR, Gratiot M., et al. In vitro and in vivo effects of a farnesyltransferase inhibitor on Nf1-deficient hematopoietic cells. Blood. 1999;94:2469-2476.[Abstract/Free Full Text]
• Dasgupta B., Li W., Perry A., et al. Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes. Cancer Res. 2005;65:236-245.[Abstract/Free Full Text]
• Khalaf WF, Yang FC, Chen S., et al. K-ras is critical for modulating multiple c-kit-mediated cellular functions in wild-type and Nf1+/- mast cells. J Immunol. 2007;178:2527-2534.[Abstract/Free Full Text]
• Morgan KJ, Rowley MA, Wiesner SM, et al. The GAP-related domain of neurofibromin attenuates proliferation and downregulates N- and K-RAS activation in Nf1-negative AML cells. Leuk Res. 2007;31:1107-1113.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Dasgupta B., Yi Y., Chen DY, et al. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res. 2005;65:2755-2760.[Abstract/Free Full Text]
• Sandsmark DK, Pelletier C., Weber JD, et al. Mammalian target of rapamycin: master regulator of cell growth in the nervous system. Histol Histopathol. 2007;22:895-903.[Web of Science][Medline] [Order article via Infotrieve]
• Guertin DA, Sabatini DM Defining the role of mTOR in cancer. Cancer Cell. 2007;12:9-22.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Pelletier CL, Maggi LB Jr, Brady SN, et al. TSC1 sets the rate of ribosome export and protein synthesis through nucleophosmin translation. Cancer Res. 2007;67:1609-1617.[Abstract/Free Full Text]
• Sandsmark DK, Zhang H., Hegedus B., et al. Nucleophosmin mediates mammalian target of rapamycin-dependent actin cytoskeleton dynamics and proliferation in neurofibromin-deficient astrocytes. Cancer Res. 2007;67:4790-4799.[Abstract/Free Full Text]
• Yu Y., Maggi LB Jr, Brady SN, et al. Nucleophosmin is essential for ribosomal protein L5 nuclear export. Mol Cell Biol. 2006;26:3798-3809.[Abstract/Free Full Text]
• Nellist M., Janssen B., Ward CJ, et al. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. 1993;75:1305-1315.[Web of Science][Medline] [Order article via Infotrieve]
• van Slegtenhorst M., de Hoogt R., Hermans C., et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 1997;277:805-808.[Abstract/Free Full Text]
• Garami A., Zwartkruis FJ, Nobukuni T., et al. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell. 2003;11:1457-1466.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Inoki K., Li Y., Xu T., et al. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 2003;17:1829-1834.[Abstract/Free Full Text]
• Tee AR, Manning BD, Roux PP, et al. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol. 2003;13:1259-1268.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Franz DN, Leonard J., Tudor C., et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol. 2006;59:490-498.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Haas-Kogan D., Shalev N., Wong M., et al. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol. 1998;8:1195-1198.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Maehama T., Dixon JE The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998;273:13375-13378.[Abstract/Free Full Text]
• Wang L., Harris TE, Roth RA, et al. PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J Biol Chem. 2007;282:20036-20044.[Abstract/Free Full Text]
• Johannessen CM, Reczek EE, James MF, et al. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A. 2005;102:8573-8578.[Abstract/Free Full Text]
• Tee AR, Anjum R., Blenis J. Inactivation of the tuberous sclerosis complex-1 and -2 gene products occurs by phosphoinositide 3-kinase/Akt-dependent and -independent phosphorylation of tuberin. J Biol Chem. 2003;278:37288-37296.[Abstract/Free Full Text]
• Collins VP, James CD Gene and chromosomal alterations associated with the development of human gliomas. Faseb J. 1993;7:926-930.[Abstract]
• Calabrese C., Poppleton H., Kocak M., et al. A perivascular niche for brain tumor stem cells. Cancer Cell. 2007;11:69-82.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Watters JJ, Schartner JM, Badie B. Microglia function in brain tumors. J Neurosci Res. 2005;81:447-455.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Badie B., Schartner J. Role of microglia in glioma biology. Microsc Res Tech. 2001;54:106-113.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Wesolowska A., Kwiatkowska A., Slomnicki L., et al. Microglia-derived TGF-beta as an important regulator of glioblastoma invasion-an inhibition of TGF-beta-dependent effects by shRNA against human TGF-beta type II receptor. Oncogene. 2008;27:918-930.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Weissenberger J., Loeffler S., Kappeler A., et al. IL-6 is required for glioma development in a mouse model. Oncogene. 2004;23:3308-3316.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Zhu Y., Ghosh P., Charnay P., et al. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science. 2002;296:920-922.[Abstract/Free Full Text]
• Bajenaru ML, Zhu Y., Hedrick NM, et al. Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation. Mol Cell Biol. 2002;22:5100-5113.[Abstract/Free Full Text]
• Bajenaru ML, Hernandez MR, Perry A., et al. Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res. 2003;63:8573-8577.[Abstract/Free Full Text]
• Graeber MB, Scheithauer BW, Kreutzberg GW Microglia in brain tumors. Glia. 2002;40:252-259.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Daginakatte GC, Gutmann DH Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth. Hum Mol Genet. 2007;16:1098-1112.[Abstract/Free Full Text]
• Adamia S., Maxwell CA, Pilarski LM Hyaluronan and hyaluronan synthases: potential therapeutic targets in cancer. Curr Drug Targets Cardiovasc Haematol Disord. 2005;5:3-14.[CrossRef][Medline] [Order article via Infotrieve]
• Yang L., Jackson E., Woerner BM, et al. Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor growth in vivo. Cancer Res. 2007;67:651-658.[Abstract/Free Full Text]
• Tong J., Hannan F., Zhu Y., et al. Neurofibromin regulates G protein-stimulated adenylyl cyclase activity. Nat Neurosci. 2002;5:95-96.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Dasgupta B., Dugan LL, Gutmann DH The neurofibromatosis 1 gene product neurofibromin regulates pituitary adenylate cyclase-activating polypeptide-mediated signaling in astrocytes. J Neurosci. 2003;23:8949-8954.[Abstract/Free Full Text]
• Warrington NM, Woerner BM, Daginakatte GC, et al. Spatiotemporal differences in CXCL12 expression and cyclic AMP underlie the unique pattern of optic glioma growth in neurofibromatosis type 1. Cancer Res. 2007;67:8588-8595.[Abstract/Free Full Text]
• Singh SK, Hawkins C., Clarke ID, et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396-401.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Galli R., Binda E., Orfanelli U., et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004;64:7011-7021.[Abstract/Free Full Text]
• Yuan X., Curtin J., Xiong Y., et al. Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene. 2004;23:9392-9400.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Hemmati HD, Nakano I., Lazareff JA, et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A. 2003;100:15178-15183.[Abstract/Free Full Text]
• Folkins C., Man S., Xu P., et al. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res. 2007;67:3560-3564.[Abstract/Free Full Text]
• Reilly KM, Loisel DA, Bronson RT, et al. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat Genet. 2000;26:109-113.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Reilly KM, Tuskan RG, Christy E., et al. Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects. Proc Natl Acad Sci U S A. 2004;101:13008-13013.[Abstract/Free Full Text]
• McConville P., Hambardzumyan D., Moody JB, et al. Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma. Clin Cancer Res. 2007;13:2897-2904.[Abstract/Free Full Text]
• Moffat BA, Chenevert TL, Lawrence TS, et al. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A. 2005;102:5524-5529.[Abstract/Free Full Text]
• Dasgupta B., Yi Y., Hegedus B., et al. Cerebrospinal fluid proteomic analysis reveals dysregulation of methionine aminopeptidase-2 expression in human and mouse neurofibromatosis 1-associated glioma. Cancer Res. 2005;65:9843-9850.[Abstract/Free Full Text]
• Gutmann DH, Hunter-Schaedle K., Shannon KM Harnessing preclinical mouse models to inform human clinical cancer trials. J Clin Invest. 2006;116:847-852.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Hegedus B., Banerjee D., Yeh TH, et al. Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma. Cancer Res. 2008;68:1520-1528.[Abstract/Free Full Text]
• Banerjee D., Hegedus B., Gutmann DH, et al. Detection and measurement of neurofibromatosis-1 mouse optic glioma in vivo. Neuroimage. 2007;35:1434-1437.[CrossRef][Medline] [Order article via Infotrieve]
• Gorre ME, Mohammed M., Ellwood K., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876-880.[Abstract/Free Full Text]
• Shah NP, Nicoll JM, Nagar B., et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002;2:117-125.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Giuriato S., Felsher DW How cancers escape their oncogene habit. Cell Cycle. 2003;2:329-332.[Medline] [Order article via Infotrieve]

Journal of Child Neurology, Vol. 23, No. 10, 1186-1194 (2008)
DOI: 10.1177/0883073808321061


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. A. Brumback Child Neurologists Should Be Interested In Brain Tumors! J Child Neurol, November 1, 2009; 24(11): 1338 - 1340. [PDF]

				A. J. Sievert and M. J. Fisher Pediatric Low-Grade Gliomas J Child Neurol, November 1, 2009; 24(11): 1397 - 1408. [Abstract] [PDF]

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Gutmann, D. H. Search for Related Content PubMed PubMed Citation Articles by Gutmann, D. H. Social Bookmarking                         What's this?